Storia in 4 fonti

FDA places partial hold on Biohaven’s epilepsy drug

Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 g fa

FDA places partial hold on Biohaven’s epilepsy drug

Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.

originale

Timeline cronologica

giovedì 10 settembre 2026·biopharmadive.com
FDA places partial hold on Biohaven’s epilepsy drug
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
giovedì 10 settembre 2026·investors.com
Biohaven's Ratty Setback; How Xenon Benefits
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.

FDA places partial hold on Biohaven’s epilepsy drug

Confronto fonti

FDA places partial hold on Biohaven’s epilepsy drug

Timeline cronologica

FDA places partial hold on Biohaven’s epilepsy drug

Biohaven's Ratty Setback; How Xenon Benefits

FDA places partial hold on Biohaven's ion channel drug

Biohaven's Ratty Setback; How Xenon Benefits

Why Is Biohaven Stock Tumbling Today? - Biohaven (NYSE:BHVN)

FDA places partial hold on Biohaven's ion channel drug

Why Is Biohaven Stock Tumbling Today? - Biohaven (NYSE:BHVN)